-
1
-
-
18544380239
-
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
-
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002;8:793-800.
-
(2002)
Nat Med
, vol.8
, pp. 793-800
-
-
Dong, H.1
Strome, S.E.2
Salomao, D.R.3
Tamura, H.4
Hirano, F.5
Flies, D.B.6
-
2
-
-
84859128199
-
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
-
Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37.
-
(2012)
Sci Transl Med
, vol.4
, pp. 127ra37
-
-
Taube, J.M.1
Anders, R.A.2
Young, G.D.3
Xu, H.4
Sharma, R.5
McMiller, T.L.6
-
3
-
-
70349569569
-
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
-
Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537-44.
-
(2009)
Blood
, vol.114
, pp. 1537-1544
-
-
Ahmadzadeh, M.1
Johnson, L.A.2
Heemskerk, B.3
Wunderlich, J.R.4
Dudley, M.E.5
White, D.E.6
-
4
-
-
33846118474
-
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
-
Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13:84-8.
-
(2007)
Nat Med
, vol.13
, pp. 84-88
-
-
Parsa, A.T.1
Waldron, J.S.2
Panner, A.3
Crane, C.A.4
Parney, I.F.5
Barry, J.J.6
-
5
-
-
58249112908
-
PI(3) kinase is associatedwithamechanismofimmunoresistance inbreast and prostate cancer
-
Crane CA, Panner A, Murray JC, Wilson SP, Xu H, Chen L, et al. PI(3) kinase is associatedwithamechanismofimmunoresistance inbreast and prostate cancer. Oncogene 2009;28:306-12.
-
(2009)
Oncogene
, vol.28
, pp. 306-312
-
-
Crane, C.A.1
Panner, A.2
Murray, J.C.3
Wilson, S.P.4
Xu, H.5
Chen, L.6
-
6
-
-
84890020587
-
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
-
Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3:1355-63.
-
(2013)
Cancer Discov
, vol.3
, pp. 1355-1363
-
-
Akbay, E.A.1
Koyama, S.2
Carretero, J.3
Altabef, A.4
Tchaicha, J.H.5
Christensen, C.L.6
-
7
-
-
78049370405
-
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing hodgkin lymphoma and primary mediastinal large B-cell lymphoma
-
Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010;116:3268-77.
-
(2010)
Blood
, vol.116
, pp. 3268-3277
-
-
Green, M.R.1
Monti, S.2
Rodig, S.J.3
Juszczynski, P.4
Currie, T.5
O'Donnell, E.6
-
8
-
-
58549102319
-
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
-
Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 2008;105:20852-7.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 20852-20857
-
-
Marzec, M.1
Zhang, Q.2
Goradia, A.3
Raghunath, P.N.4
Liu, X.5
Paessler, M.6
-
9
-
-
73349128709
-
Integrated molecular and clinical analysis of AKT activation in metastatic melanoma
-
Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 2009;15:7538-46.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 7538-7546
-
-
Davies, M.A.1
Stemke-Hale, K.2
Lin, E.3
Tellez, C.4
Deng, W.5
Gopal, Y.N.6
-
10
-
-
84873336707
-
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition
-
Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013;19:598-609.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 598-609
-
-
Jiang, X.1
Zhou, J.2
Giobbie-Hurder, A.3
Wargo, J.4
Hodi, F.S.5
-
11
-
-
33745859743
-
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
-
Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006;203:1651-6.
-
(2006)
J Exp Med
, vol.203
, pp. 1651-1656
-
-
Sumimoto, H.1
Imabayashi, F.2
Iwata, T.3
Kawakami, Y.4
-
12
-
-
84864722943
-
NRAS mutation status is an independent prognostic factor in metastatic melanoma
-
Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118:4014-23.
-
(2012)
Cancer
, vol.118
, pp. 4014-4023
-
-
Jakob, J.A.1
Bassett, R.L.2
Ng, C.S.3
Curry, J.L.4
Joseph, R.W.5
Alvarado, G.C.6
-
13
-
-
67349167716
-
Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma
-
Greene VR, Johnson MM, Grimm EA, Ellerhorst JA. Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Derm 2009;129: 1483-8.
-
(2009)
J Invest Derm
, vol.129
, pp. 1483-1488
-
-
Greene, V.R.1
Johnson, M.M.2
Grimm, E.A.3
Ellerhorst, J.A.4
-
14
-
-
84878944625
-
Predictors of BRAF mutation in melanocytic nevi: Analysis across regions with different UV radiation exposure
-
Karram S, Novy M, Saroufim M, Loya A, Taraif S, Houreih MA, et al. Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure. Am J Dermatopathol 2013;35:412-8.
-
(2013)
Am J Dermatopathol
, vol.35
, pp. 412-418
-
-
Karram, S.1
Novy, M.2
Saroufim, M.3
Loya, A.4
Taraif, S.5
Houreih, M.A.6
-
15
-
-
84863116743
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
-
Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
-
(2012)
N Engl J Med
, vol.366
, pp. 707-714
-
-
Sosman, J.A.1
Kim, K.B.2
Schuchter, L.3
Gonzalez, R.4
Pavlick, A.C.5
Weber, J.S.6
-
16
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
-
17
-
-
77954801079
-
Improved survival with ipilimumabinpatients withmetastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumabinpatients withmetastatic melanoma. N Engl J Med 2010;363:711-23.
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
-
18
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
-
(2012)
N Engl J Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
Hwu, W.J.4
Topalian, S.L.5
Hwu, P.6
-
19
-
-
84898973055
-
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
-
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30.
-
(2014)
J Clin Oncol
, vol.32
, pp. 1020-1030
-
-
Topalian, S.L.1
Sznol, M.2
McDermott, D.F.3
Kluger, H.M.4
Carvajal, R.D.5
Sharfman, W.H.6
-
20
-
-
84904024273
-
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
-
Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-74.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 5064-5074
-
-
Taube, J.M.1
Klein, A.2
Brahmer, J.R.3
Xu, H.4
Pan, X.5
Kim, J.H.6
-
21
-
-
84885521154
-
PTEN functions as a melanoma tumor suppressor by promoting host immune response
-
Dong Y, Richards JA, Gupta R, Aung PP, Emley A, Kluger Y, et al. PTEN functions as a melanoma tumor suppressor by promoting host immune response. Oncogene 2014;33:4632-42.
-
(2014)
Oncogene
, vol.33
, pp. 4632-4642
-
-
Dong, Y.1
Richards, J.A.2
Gupta, R.3
Aung, P.P.4
Emley, A.5
Kluger, Y.6
-
22
-
-
84903831602
-
Effects of MAPK and PI3K pathwayson PD-L1 expressioninmelanoma
-
Atefi M, Avramis E, Lassen A, Wong DJL, Robert L, Foulad D, et al. Effects of MAPK and PI3K pathwayson PD-L1 expressioninmelanoma. Clin Can Res 2014;20:3446-57.
-
(2014)
Clin can Res
, vol.20
, pp. 3446-3457
-
-
Atefi, M.1
Avramis, E.2
Lassen, A.3
Wong, D.J.L.4
Robert, L.5
Foulad, D.6
-
23
-
-
84897404380
-
Programmed cell deathligand 1 expression in surgically resected stage I pulmonary adenocarci-noma and its correlation with driver mutations and clinical outcomes
-
Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell deathligand 1 expression in surgically resected stage I pulmonary adenocarci-noma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014;50:1361-9.
-
(2014)
Eur J Cancer
, vol.50
, pp. 1361-1369
-
-
Yang, C.Y.1
Lin, M.W.2
Chang, Y.L.3
Wu, C.T.4
Yang, P.C.5
-
24
-
-
84863393623
-
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma
-
Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Can Res 2012;18:1386-94.
-
(2012)
Clin can Res
, vol.18
, pp. 1386-1394
-
-
Wilmott, J.S.1
Long, G.V.2
Howle, J.R.3
Haydu, L.E.4
Sharma, R.N.5
Thompson, J.F.6
-
25
-
-
84874872137
-
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
-
Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013;19: 1225-31.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 1225-1231
-
-
Frederick, D.T.1
Piris, A.2
Cogdill, A.P.3
Cooper, Z.A.4
Lezcano, C.5
Ferrone, C.R.6
|